Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

The suit stems from the diss track “Not Like Us” by Kendrick Lamar, another UMG artist. Drake’s legal complaint also again accuses UMG of using bots on Spotify and other streaming platforms ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark ...

Use of GLP-1 receptor agonists reduced the risk of kidney failure and individual MACE components compared with placebo among patients with or without diabetes. Glucagon-like peptide-1 receptor ...